• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

12.38 +0.68 (+5.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,738,204
Open 11.54
Bid (Size) 12.38 (500)
Ask (Size) 12.60 (200)
Prev. Close 11.70
Today's Range 11.33 - 12.61
52wk Range 3.895 - 14.93
Shares Outstanding 54,532,614
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
March 19, 2026
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships. 
Via The Motley Fool
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
March 19, 2026
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+51.5%
+51.5%
1 Month
+5.7%
+5.7%
3 Month
+46.9%
+46.9%
6 Month
+18.4%
+18.4%
1 Year
+83.4%
+83.4%

More News

Read More
News headline image
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
March 09, 2026
Via Benzinga
Topics Stocks
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
February 23, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
February 05, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
January 12, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
December 04, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
December 03, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
December 01, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
November 24, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
November 20, 2025
Via Benzinga
News headline image
This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
November 20, 2025
Via Benzinga
News headline image
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
November 20, 2025
Via Benzinga
News headline image
Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday ↗
November 14, 2025
Via Benzinga
News headline image
ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
November 13, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
November 13, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
November 06, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Oric Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Oric Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Oric Pharmaceuticals, Inc. - Common Stock trade on?
Oric Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock is ORIC on the Nasdaq Stock Market
What is the current price of Oric Pharmaceuticals, Inc. - Common Stock?
The current price of Oric Pharmaceuticals, Inc. - Common Stock is 12.38
When was Oric Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Oric Pharmaceuticals, Inc. - Common Stock was at 03/26/26 04:00 PM ET
What is the market capitalization of Oric Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Oric Pharmaceuticals, Inc. - Common Stock is 675.11M
How many shares of Oric Pharmaceuticals, Inc. - Common Stock are outstanding?
Oric Pharmaceuticals, Inc. - Common Stock has 675M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap